Actavis Inc (ACT) 207.39 $ACT
Actavis, BitAuto Among Leading World Stocks In Bases
at Investor's Business Daily - Tue Jun 10, 5:50PM CDT
Six of the 10 stocks listed on the Top World Stocks list in Tuesday's IBD are pecking away at new highs. Some are still in buying range after clearing bases. Four others are building bases. One minor catch: They are all late-stage patterns. Late...
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.
Lannett In Buying Range After Breakout From Cup Base
at Investor's Business Daily - Tue Jun 10, 3:35PM CDT
Generic-drug maker Lannett (LCI) is in buying range following a breakout from a cup-without-handle base. The stock is within the 5% buy area after succeeding Monday in its third try to clear the 46.61 buy point. The previous attempts last Thursday...
Fitch Rates New Actavis Bonds 'BBB-'; Outlook Stable
Business Wire - Tue Jun 10, 9:55AM CDT
Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release.
Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.
Actavis Finalizes Agreement Related to Asacol® HD Patent Challenge Litigation
PR Newswire - Mon Jun 09, 4:54PM CDT
Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol® HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013.
Why I Like Actavis Stock
Mohsin Saeed, The Motley Fool - Motley Fool - Mon Jun 09, 1:12PM CDT
Investments in small capitalization biotechnology companies are fraught with risks. Most bio-techs rely on a single or a few trial candidates to determine their entire valuations. With little or no revenues, the downside to these stocks is immense. A...
Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations"
to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.
Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company" today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.
Several IBD 50 Names Set Up In Stock Picker's Market
at Investor's Business Daily - Fri Jun 06, 4:58PM CDT
A nascent market uptrend, confirmed by the Nasdaq and S&P 500 on May 27, is looking pretty good. Distribution days, or higher-volume declines, have been nonexistent so far and growth stocks overall are holding up well. The IBD 50 is essentially flat...
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market
More Stock Leaders Emerge From More Industry Groups
at Investor's Business Daily - Thu Jun 05, 5:03PM CDT
The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends. The first trend: Since the Nasdaq's May 27 confirmation of a new market uptrend, more stocks are hitting proper buy points, while others are...
Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...
Top New Buys: Funds Pile Into Actavis, chip stocks
at Investor's Business Daily - Tue Jun 03, 5:35PM CDT
After a three-month-long correction, the Nasdaq composite index followed through on March 27. That means it's time to look for stocks breaking out of sound bases. But mutual funds have already been busy in recent months, their buying helping to form...
Health Care Sector Equities Scrutiny -- Research on AVANIR Pharma, Zoetis, Actavis, and Mallinckrodt
PR Newswire - Tue Jun 03, 6:50AM CDT
On Monday, June 2, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average edged 0.16% higher to finish the day at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. During the session gains in the Materials, Industrials, and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Energy, and Information Technology sectors. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, with the index advancing 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT) and Mallinckrodt PLC (NYSE: MNK). Free technical research on AVNR, ZTS, ACT and MNK can be downloaded upon signing up at:
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
New Employers Listed For Annual Life Science Hiring Event
PR Newswire - Mon Jun 02, 9:45AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014. The annual hiring event is being sponsored by Novo Nordisk. Additional event sponsors thus far include Covance and top generic drug company, Actavis, Inc. In addition to returning companies such as Johnson & Johnson, LifeCell and Cubist Pharmaceuticals there have been many companies added since April. Recent additions to the exhibitor list are Daiichi Sankyo, Musculoskeletal Transplant Foundation (MTF), DSM Nutritional Products, Acorda Therapeutics, GE Healthcare, Amneal Pharmaceuticals and Actavis, Inc. More companies will be added during the upcoming summer months creating the largest Life Science career fair for 2014 in the Tri-State area.
Enzo Biochem names James M O'Brien as senior VP of Finance
M2 - Mon Jun 02, 6:03AM CDT
Clinical laboratory company Enzo Biochem (NYSE:ENZ) revealed on Friday the election of James M O'Brien as senior vice president of its Finance, succeeding Andrew Crescenzo.
Actavis Announces Nuvigil® Patent Challenge Settlement
PR Newswire - Fri May 30, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil® is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy.
1 Big Pharma Stock in More Danger than Investors Realize
David Williamson, The Motley Fool - Motley Fool - Fri May 30, 1:05PM CDT
Eli Lilly (NYSE: LLY) just lost a patent fight for its lung cancer drug Alimta to generic drug maker Actavis (NYSE: ACT). This UK court decision would cut the blockbuster drug's patent short by 6 years to 2015, not only in the United Kingdom,...
Actavis, BitAuto Among Leading World Stocks In Bases
at Investor's Business Daily - Tue Jun 10, 5:50PM CDT
Six of the 10 stocks listed on the Top World Stocks list in Tuesday's IBD are pecking away at new highs. Some are still in buying range after clearing bases. Four others are building bases. One minor catch: They are all late-stage patterns. Late...
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.
Lannett In Buying Range After Breakout From Cup Base
at Investor's Business Daily - Tue Jun 10, 3:35PM CDT
Generic-drug maker Lannett (LCI) is in buying range following a breakout from a cup-without-handle base. The stock is within the 5% buy area after succeeding Monday in its third try to clear the 46.61 buy point. The previous attempts last Thursday...
Fitch Rates New Actavis Bonds 'BBB-'; Outlook Stable
Business Wire - Tue Jun 10, 9:55AM CDT
Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release.
Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.
Actavis Finalizes Agreement Related to Asacol® HD Patent Challenge Litigation
PR Newswire - Mon Jun 09, 4:54PM CDT
Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol® HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013.
Why I Like Actavis Stock
Mohsin Saeed, The Motley Fool - Motley Fool - Mon Jun 09, 1:12PM CDT
Investments in small capitalization biotechnology companies are fraught with risks. Most bio-techs rely on a single or a few trial candidates to determine their entire valuations. With little or no revenues, the downside to these stocks is immense. A...
Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations"
to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014. Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company"
today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014. Several IBD 50 Names Set Up In Stock Picker's Market
at Investor's Business Daily - Fri Jun 06, 4:58PM CDT
A nascent market uptrend, confirmed by the Nasdaq and S&P 500 on May 27, is looking pretty good. Distribution days, or higher-volume declines, have been nonexistent so far and growth stocks overall are holding up well. The IBD 50 is essentially flat...
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market
More Stock Leaders Emerge From More Industry Groups
at Investor's Business Daily - Thu Jun 05, 5:03PM CDT
The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends. The first trend: Since the Nasdaq's May 27 confirmation of a new market uptrend, more stocks are hitting proper buy points, while others are...
Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...
Top New Buys: Funds Pile Into Actavis, chip stocks
at Investor's Business Daily - Tue Jun 03, 5:35PM CDT
After a three-month-long correction, the Nasdaq composite index followed through on March 27. That means it's time to look for stocks breaking out of sound bases. But mutual funds have already been busy in recent months, their buying helping to form...
Health Care Sector Equities Scrutiny -- Research on AVANIR Pharma, Zoetis, Actavis, and Mallinckrodt
PR Newswire - Tue Jun 03, 6:50AM CDT
On Monday, June 2, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average edged 0.16% higher to finish the day at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. During the session gains in the Materials, Industrials, and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Energy, and Information Technology sectors. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, with the index advancing 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT) and Mallinckrodt PLC (NYSE: MNK). Free technical research on AVNR, ZTS, ACT and MNK can be downloaded upon signing up at:
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
New Employers Listed For Annual Life Science Hiring Event
PR Newswire - Mon Jun 02, 9:45AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014. The annual hiring event is being sponsored by Novo Nordisk. Additional event sponsors thus far include Covance and top generic drug company, Actavis, Inc. In addition to returning companies such as Johnson & Johnson, LifeCell and Cubist Pharmaceuticals there have been many companies added since April. Recent additions to the exhibitor list are Daiichi Sankyo, Musculoskeletal Transplant Foundation (MTF), DSM Nutritional Products, Acorda Therapeutics, GE Healthcare, Amneal Pharmaceuticals and Actavis, Inc. More companies will be added during the upcoming summer months creating the largest Life Science career fair for 2014 in the Tri-State area.
Enzo Biochem names James M O'Brien as senior VP of Finance
M2 - Mon Jun 02, 6:03AM CDT
Clinical laboratory company Enzo Biochem (NYSE:ENZ) revealed on Friday the election of James M O'Brien as senior vice president of its Finance, succeeding Andrew Crescenzo.
Actavis Announces Nuvigil® Patent Challenge Settlement
PR Newswire - Fri May 30, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil® is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy.
1 Big Pharma Stock in More Danger than Investors Realize
David Williamson, The Motley Fool - Motley Fool - Fri May 30, 1:05PM CDT
Eli Lilly (NYSE: LLY) just lost a patent fight for its lung cancer drug Alimta to generic drug maker Actavis (NYSE: ACT). This UK court decision would cut the blockbuster drug's patent short by 6 years to 2015, not only in the United Kingdom,...
